LivaNova (NASDAQ:LIVN) Receives Buy Rating from Needham & Company LLC

LivaNova (NASDAQ:LIVN)‘s stock had its “buy” rating reissued by equities research analysts at Needham & Company LLC in a research note issued on Monday,Benzinga reports. They currently have a $75.00 price objective on the stock. Needham & Company LLC’s price target would indicate a potential upside of 47.96% from the stock’s previous close.

Several other equities analysts have also weighed in on the company. Baird R W raised LivaNova from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 17th. Mizuho reduced their price target on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating on the stock in a research report on Thursday, October 31st. StockNews.com downgraded shares of LivaNova from a “strong-buy” rating to a “buy” rating in a research note on Saturday, November 16th. The Goldman Sachs Group assumed coverage on shares of LivaNova in a research note on Friday, October 4th. They issued a “buy” rating and a $65.00 target price on the stock. Finally, Robert W. Baird upped their price target on shares of LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $69.17.

LivaNova Price Performance

Shares of LivaNova stock opened at $50.69 on Monday. The business’s fifty day moving average price is $52.18 and its 200 day moving average price is $52.30. LivaNova has a twelve month low of $42.75 and a twelve month high of $64.47. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. The stock has a market capitalization of $2.75 billion, a P/E ratio of 120.69 and a beta of 1.01.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Fifth Third Bancorp increased its stake in LivaNova by 97.1% during the 2nd quarter. Fifth Third Bancorp now owns 674 shares of the company’s stock worth $37,000 after buying an additional 332 shares during the period. Hexagon Capital Partners LLC grew its stake in shares of LivaNova by 117.8% during the second quarter. Hexagon Capital Partners LLC now owns 684 shares of the company’s stock valued at $37,000 after acquiring an additional 370 shares in the last quarter. Lazard Asset Management LLC purchased a new stake in shares of LivaNova during the first quarter worth about $84,000. Canada Pension Plan Investment Board acquired a new position in shares of LivaNova in the second quarter worth about $88,000. Finally, Acadian Asset Management LLC purchased a new position in LivaNova in the first quarter valued at about $94,000. 97.64% of the stock is owned by institutional investors and hedge funds.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.